In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator

Hung Jen Tang, Wen Chien Ko, Chi Chung Chen, Po Lin Chen, Han Siong Toh, Tzu Chieh Weng, Wen Liang Yu, Shyh Ren Chiang, Yin Ching Chuang

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Salmonella is an important, worldwide food-borne pathogen. Resistance to fluoroquinolones and cephalosporins has been increasingly reported, and new therapeutic agents are desperately needed. In this study, we evaluated the in vitro antimicrobial susceptibility of clinical nontyphoidal Salmonella isolates to tigecycline. Antibacterial activity of tigecycline, ceftriaxone, and ciprofloxacin were investigated by time-kill studies and the murine peritonitis model. The MIC 50/MIC 90 values of tigecycline, ceftriaxone, and ciprofloxacin against 76 Salmonella isolates were 0.25/0.5, 1/8, and 0.125/0.5 μg/ml, respectively. The intracellular inhibitory activity of tigecycline at 0.5 μg/ml (1x MIC) against Salmonella isolates in human peripheral blood mononuclear cells was sustained for 24 h. In a mouse peritonitis model, tigecycline reduced the extracellular and intracellular bacterial counts from 10 7 CFU/ml and 10 5 CFU/ml, respectively, to an undetectable level within 96 h. The results were similar to those obtained with ceftriaxone. The survival rate of mice exposed to tigecycline after being infected by an inoculum of 1 × 10 5 CFU was 80%, and that of mice exposed to ceftriaxone was 100%. When the inoculum was increased to 1.3 × 10 6 CFU, the survival rate of mice treated by tigecycline was 20%, and that of mice exposed to ceftriaxone was 0% (P = 0.2). When a ceftriaxone- and ciprofloxacin-resistant but tigecycline- susceptible isolate was tested, mice treated by tigecycline had a higher survival rate than those treated by ceftriaxone (15/20 [75%] versus 6/20 [30%]; P = 0.011). Our results suggest that tigecycline is at least as effective as ceftriaxone for murine Salmonella infections and warrants further clinical investigations to delineate its potential against human Salmonella infections.

Original languageEnglish
Pages (from-to)2755-2759
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume55
Issue number6
DOIs
Publication statusPublished - Jun 2011
Externally publishedYes

Fingerprint

Ceftriaxone
Salmonella
Ciprofloxacin
Salmonella Infections
Peritonitis
tigecycline
In Vitro Techniques
Bacterial Load
Fluoroquinolones
Cephalosporins
Blood Cells
Food

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator. / Tang, Hung Jen; Ko, Wen Chien; Chen, Chi Chung; Chen, Po Lin; Toh, Han Siong; Weng, Tzu Chieh; Yu, Wen Liang; Chiang, Shyh Ren; Chuang, Yin Ching.

In: Antimicrobial Agents and Chemotherapy, Vol. 55, No. 6, 06.2011, p. 2755-2759.

Research output: Contribution to journalArticle

Tang, Hung Jen ; Ko, Wen Chien ; Chen, Chi Chung ; Chen, Po Lin ; Toh, Han Siong ; Weng, Tzu Chieh ; Yu, Wen Liang ; Chiang, Shyh Ren ; Chuang, Yin Ching. / In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator. In: Antimicrobial Agents and Chemotherapy. 2011 ; Vol. 55, No. 6. pp. 2755-2759.
@article{4f17f5571e17455a972757bb42d9f495,
title = "In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator",
abstract = "Salmonella is an important, worldwide food-borne pathogen. Resistance to fluoroquinolones and cephalosporins has been increasingly reported, and new therapeutic agents are desperately needed. In this study, we evaluated the in vitro antimicrobial susceptibility of clinical nontyphoidal Salmonella isolates to tigecycline. Antibacterial activity of tigecycline, ceftriaxone, and ciprofloxacin were investigated by time-kill studies and the murine peritonitis model. The MIC 50/MIC 90 values of tigecycline, ceftriaxone, and ciprofloxacin against 76 Salmonella isolates were 0.25/0.5, 1/8, and 0.125/0.5 μg/ml, respectively. The intracellular inhibitory activity of tigecycline at 0.5 μg/ml (1x MIC) against Salmonella isolates in human peripheral blood mononuclear cells was sustained for 24 h. In a mouse peritonitis model, tigecycline reduced the extracellular and intracellular bacterial counts from 10 7 CFU/ml and 10 5 CFU/ml, respectively, to an undetectable level within 96 h. The results were similar to those obtained with ceftriaxone. The survival rate of mice exposed to tigecycline after being infected by an inoculum of 1 × 10 5 CFU was 80{\%}, and that of mice exposed to ceftriaxone was 100{\%}. When the inoculum was increased to 1.3 × 10 6 CFU, the survival rate of mice treated by tigecycline was 20{\%}, and that of mice exposed to ceftriaxone was 0{\%} (P = 0.2). When a ceftriaxone- and ciprofloxacin-resistant but tigecycline- susceptible isolate was tested, mice treated by tigecycline had a higher survival rate than those treated by ceftriaxone (15/20 [75{\%}] versus 6/20 [30{\%}]; P = 0.011). Our results suggest that tigecycline is at least as effective as ceftriaxone for murine Salmonella infections and warrants further clinical investigations to delineate its potential against human Salmonella infections.",
author = "Tang, {Hung Jen} and Ko, {Wen Chien} and Chen, {Chi Chung} and Chen, {Po Lin} and Toh, {Han Siong} and Weng, {Tzu Chieh} and Yu, {Wen Liang} and Chiang, {Shyh Ren} and Chuang, {Yin Ching}",
year = "2011",
month = "6",
doi = "10.1128/AAC.01807-10",
language = "English",
volume = "55",
pages = "2755--2759",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - In vitro and in vivo intracellular killing effects of tigecycline against clinical nontyphoid Salmonella isolates using ceftriaxone as a comparator

AU - Tang, Hung Jen

AU - Ko, Wen Chien

AU - Chen, Chi Chung

AU - Chen, Po Lin

AU - Toh, Han Siong

AU - Weng, Tzu Chieh

AU - Yu, Wen Liang

AU - Chiang, Shyh Ren

AU - Chuang, Yin Ching

PY - 2011/6

Y1 - 2011/6

N2 - Salmonella is an important, worldwide food-borne pathogen. Resistance to fluoroquinolones and cephalosporins has been increasingly reported, and new therapeutic agents are desperately needed. In this study, we evaluated the in vitro antimicrobial susceptibility of clinical nontyphoidal Salmonella isolates to tigecycline. Antibacterial activity of tigecycline, ceftriaxone, and ciprofloxacin were investigated by time-kill studies and the murine peritonitis model. The MIC 50/MIC 90 values of tigecycline, ceftriaxone, and ciprofloxacin against 76 Salmonella isolates were 0.25/0.5, 1/8, and 0.125/0.5 μg/ml, respectively. The intracellular inhibitory activity of tigecycline at 0.5 μg/ml (1x MIC) against Salmonella isolates in human peripheral blood mononuclear cells was sustained for 24 h. In a mouse peritonitis model, tigecycline reduced the extracellular and intracellular bacterial counts from 10 7 CFU/ml and 10 5 CFU/ml, respectively, to an undetectable level within 96 h. The results were similar to those obtained with ceftriaxone. The survival rate of mice exposed to tigecycline after being infected by an inoculum of 1 × 10 5 CFU was 80%, and that of mice exposed to ceftriaxone was 100%. When the inoculum was increased to 1.3 × 10 6 CFU, the survival rate of mice treated by tigecycline was 20%, and that of mice exposed to ceftriaxone was 0% (P = 0.2). When a ceftriaxone- and ciprofloxacin-resistant but tigecycline- susceptible isolate was tested, mice treated by tigecycline had a higher survival rate than those treated by ceftriaxone (15/20 [75%] versus 6/20 [30%]; P = 0.011). Our results suggest that tigecycline is at least as effective as ceftriaxone for murine Salmonella infections and warrants further clinical investigations to delineate its potential against human Salmonella infections.

AB - Salmonella is an important, worldwide food-borne pathogen. Resistance to fluoroquinolones and cephalosporins has been increasingly reported, and new therapeutic agents are desperately needed. In this study, we evaluated the in vitro antimicrobial susceptibility of clinical nontyphoidal Salmonella isolates to tigecycline. Antibacterial activity of tigecycline, ceftriaxone, and ciprofloxacin were investigated by time-kill studies and the murine peritonitis model. The MIC 50/MIC 90 values of tigecycline, ceftriaxone, and ciprofloxacin against 76 Salmonella isolates were 0.25/0.5, 1/8, and 0.125/0.5 μg/ml, respectively. The intracellular inhibitory activity of tigecycline at 0.5 μg/ml (1x MIC) against Salmonella isolates in human peripheral blood mononuclear cells was sustained for 24 h. In a mouse peritonitis model, tigecycline reduced the extracellular and intracellular bacterial counts from 10 7 CFU/ml and 10 5 CFU/ml, respectively, to an undetectable level within 96 h. The results were similar to those obtained with ceftriaxone. The survival rate of mice exposed to tigecycline after being infected by an inoculum of 1 × 10 5 CFU was 80%, and that of mice exposed to ceftriaxone was 100%. When the inoculum was increased to 1.3 × 10 6 CFU, the survival rate of mice treated by tigecycline was 20%, and that of mice exposed to ceftriaxone was 0% (P = 0.2). When a ceftriaxone- and ciprofloxacin-resistant but tigecycline- susceptible isolate was tested, mice treated by tigecycline had a higher survival rate than those treated by ceftriaxone (15/20 [75%] versus 6/20 [30%]; P = 0.011). Our results suggest that tigecycline is at least as effective as ceftriaxone for murine Salmonella infections and warrants further clinical investigations to delineate its potential against human Salmonella infections.

UR - http://www.scopus.com/inward/record.url?scp=79956324639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956324639&partnerID=8YFLogxK

U2 - 10.1128/AAC.01807-10

DO - 10.1128/AAC.01807-10

M3 - Article

C2 - 21402846

AN - SCOPUS:79956324639

VL - 55

SP - 2755

EP - 2759

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -